| __timestamp | ADMA Biologics, Inc. | Arrowhead Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 24419536 |
| Thursday, January 1, 2015 | 6745968 | 34718089 |
| Friday, January 1, 2016 | 8494742 | 40998209 |
| Sunday, January 1, 2017 | 18092835 | 32022880 |
| Monday, January 1, 2018 | 22502922 | 19110051 |
| Tuesday, January 1, 2019 | 25910757 | 26556257 |
| Wednesday, January 1, 2020 | 35050817 | 52275890 |
| Friday, January 1, 2021 | 42896889 | 80981000 |
| Saturday, January 1, 2022 | 52458024 | 124431000 |
| Sunday, January 1, 2023 | 59020000 | 90932000 |
| Monday, January 1, 2024 | 98761000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. Over the past decade, ADMA Biologics, Inc. and Arrowhead Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a staggering increase of over 1,100% in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Arrowhead Pharmaceuticals experienced a more moderate rise of approximately 270% during the same period, indicating a steady expansion approach.
Interestingly, 2022 marked a peak for Arrowhead, with expenses reaching nearly double those of ADMA. However, 2023 saw a slight decline for Arrowhead, suggesting potential strategic shifts or cost optimizations. Missing data for 2024 leaves room for speculation on future trends. These insights provide a window into the strategic priorities and operational efficiencies of these biotech players.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Summit Therapeutics Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.
ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE